Literature DB >> 22628537

Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy.

Eamon Sharkawi1, Justyna D Oleszczuk, Ciara Bergin, Leonidas Zografos.   

Abstract

INTRODUCTION: Melanoma of the iris and ciliary body may be associated with secondary glaucoma. Treatment with proton beam radiotherapy (PBRT) to the anterior segment can also elevate intraocular pressure (IOP), resulting in uncontrolled glaucoma, often requiring enucleation. This is the first prospective study of Baerveldt aqueous shunts in irradiated eyes with anterior uveal melanoma (AUM; affecting the iris or ciliary body).
METHODS: Thirty-one eyes with uncontrolled IOP following anterior segment PBRT treatment for AUM were prospectively recruited to undergo Baerveldt shunt implantation. Postoperative examinations were performed on day 1; weeks 1, 3, 6, 9; months 3, 6, 9, 12 and annually thereafter. Surgical success was defined as IOP 21 mm Hg or less and 20% reduction from baseline. All complications were recorded.
RESULTS: Mean follow-up was 15.7 months (SD ± 8.3 months). Mean interval from irradiation to shunt implantation was 2.5 years. Mean preoperative IOP was 31.0 (± 10.3) mm Hg; mean IOP at last visit was 15.0 (± 5.0) mm Hg; mean pre-operative glaucoma medications were 3.3 (± 1.3); postoperatively 0.7 (± 1.3) glaucoma medications. Surgical success rate was 86% using glaucoma medications. Four eyes had minor postoperative complications, none of which were sight threatening. There were no local tumour recurrences or systemic metastases. There were no enucleations caused by ocular hypertension.
CONCLUSIONS: Baerveldt shunts were effective in lowering IOP, with few complications, in eyes treated with total anterior segment irradiation for AUM.

Entities:  

Mesh:

Year:  2012        PMID: 22628537     DOI: 10.1136/bjophthalmol-2011-301420

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

1.  Proton beam radiotherapy of uveal melanoma.

Authors:  Bertil Damato; Andrzej Kacperek; Doug Errington; Heinrich Heimann
Journal:  Saudi J Ophthalmol       Date:  2013-07

2.  Orbital Extension of an Unsuspected Choroidal Melanoma Presumably through an Aqueous Tube Shunt.

Authors:  Hayyam Kiratli; İrem Koç; Berçin Tarlan
Journal:  Ocul Oncol Pathol       Date:  2015-11-25

3.  Trabeculectomy in patients with uveal melanoma after proton beam therapy.

Authors:  Aline I Riechardt; Dino Cordini; Matus Rehak; Annette Hager; Ira Seibel; Alexander Böker; Enken Gundlach; Jens Heufelder; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-10       Impact factor: 3.117

4.  Treatment of uncontrolled intraocular pressure secondary to uveal melanoma status post plaque radiotherapy with ab interno XEN gel stent implantation.

Authors:  Ben J Harvey; Finny T John; Christian A Leal; Brian K Firestone
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-16

5.  Baerveldt tube implantation following failed deep sclerectomy versus repeat deep sclerectomy.

Authors:  C Bergin; A Petrovic; A Mermoud; E Ravinet; E Sharkawi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-31       Impact factor: 3.117

6.  Proton beam radiation for iris melanoma: case series and review of literature.

Authors:  Jasmine Alexandra Hauzinger; Georgios Blatsios; Gertrud Haas; Claus Zehetner; Luisa Velez-Escola; Yvonne Nowosielski; Christof Seifarth; Teresa Rauchegger; Bernhard Haider; Nikolaos E Bechrakis
Journal:  BMJ Open Ophthalmol       Date:  2021-12-23

7.  Outcomes of Glaucoma Drainage Device Surgery in Eyes with Treated Uveal Melanoma.

Authors:  Nima Fatehi; Tara A McCannel; JoAnn Giaconi; Joseph Caprioli; Simon K Law; Kouros Nouri-Mahdavi
Journal:  Ocul Oncol Pathol       Date:  2018-05-02

8.  Iris melanoma presenting as childhood glaucoma.

Authors:  Briana C Gapsis; Nichelle A Warren; Matthew J Nutaitis; Leah A Bonaparte; Samuel L Cooper; Michael Ashenafi; Hans E Grossniklaus; George N Magrath
Journal:  Am J Ophthalmol Case Rep       Date:  2018-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.